Piraye Yurttas Beim, PhD

Dr. Piraye Yurttas Beim, PhD is the founder and CEO of Celmatix Therapeutics, a preclinical-stage biotech transforming women’s lives through better lifelong health. Founded in 2009 as one of the first FemTech companies, Celmatix’s mission is to accelerate precision medicine in women’s health. Under Dr. Beim's leadership, Celmatix has been recognized as one of Fast Company’s Most Innovative Companies and pioneered breakthroughs in decoding the genomic drivers of ovarian function and unlocking unprecedented insight into unique aspects of female biology and health. Dr. Beim’s publications have been widely cited, and she has been the primary inventor of many of Celmatix’s disruptive innovations, including groundbreaking drug programs for treating endometriosis, improving fertility care, and extending ovarian function. Dr. Beim has dedicated herself to innovating in women's health for more than 25 years. During her PhD work at Cornell University (Weill, NYC) and Memorial Sloan Kettering Cancer Center, she was on the front lines of the precision medicine revolution in women’s health oncology. She then completed her post-doc at the University of Cambridge (UK), focusing on the science of fertility. Dr. Beim is also widely recognized as a notable business leader and entrepreneur. She is a member of the Aspen Global Leadership Network, was named to Elle Magazine’s “Women in Tech” Power List, Inc Magazine’s 2025 Top Female Founders, Crain’s 40 Under 40 and its Notable Women in Tech, Goldman Sachs's Most Intriguing Entrepreneurs, Top 15 founders disrupting their industries by Fortune, and Rock Health's Disruptive Founder of the Year. She is also on the boards of the Center on Rural Innovation and the Endometriosis Foundation of America, where she serves as Chairman. She is an active angel investor and lives between New York City and Bridgehampton with her three children.